Lupus & antiphospholipid syndrome
Novel CSF biomarkers for diagnosis and integrated analysis of neuropsychiatric systemic lupus erythematosus: based on antibody profiling
Authors' conclusion
The dual-chips screening strategy demonstrated KLK5, L-selectin, Trappin-2, TCN2, and CST6 as CSF biomarkers for diagnosing NPSLE.
Study context
- Population
- CSF from controls, systemic lupus erythematosus (SLE) (non-NPSLE) patients and neuropsychiatric systemic lupus erythematosus (NPSLE) patients
- Comparison
- CSF protein expression in NPSLE vs SLE vs controls
- Outcome
- Novel CSF biomarkers for diagnosing NPSLE
Methodological detailsquantitative planar protein antibody microarray screening of 1000 proteins, validation with custom multiplexed protein antibody array in an independent larger cohort, LASSO and multivariable logistic regression, ROC analysis
- Quantitative planar protein antibody microarray screening of 1000 proteins
- Validation with custom multiplexed protein antibody array in an independent larger cohort
- LASSO and multivariable logistic regression
- ROC analysis
Performance
As reported in the abstract
CSF biomarkers for NPSLE
Proteins with significantly altered CSF expression across the three groups
29
Candidate biomarkers selected by protein interaction analysis
17
Differentially expressed proteins (DEPs) identified as NPSLE biomarkers in the larger cohort (TCN2, CST6, KLK5, L-selectin, Trappin-2)
5
Further findings
Association of CSF biomarkers with disease activity
- CSF biomarkers highly associated with disease activity
Molecules with remarkable changes in NPSLE CSF and hippocampus
- Molecules with remarkable changes in NPSLE CSF and hippocampus
- 6
Original publication
Novel CSF biomarkers for diagnosis and integrated analysis of neuropsychiatric systemic lupus erythematosus: based on antibody profiling. Arthritis Res Ther. Published 8 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →